TKI258, a novel, multitargeted tyrosine kinase inhibitor for the treatment of breast cancer

被引：0
|
作者：
Liu, H. [1 ]
Schulz, C. O. [1 ]
Regierer, A. C. [1 ]
Dieing, A. [1 ]
Possinger, K. [1 ]
Eucker, J. [1 ]
机构：
[1] Charite Campus Mitte, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14625
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II Results of Dovitinib (TKI258) in Patients with Metastatic Renal Cell Cancer
    Escudier, Bernard
    Gruenwald, Viktor
    Ravaud, Alain
    Ou, Yen-Chuan
    Castellano, Daniel
    Lin, Chia-Chi
    Gschwend, Juergen E.
    Harzstark, Andrea
    Beall, Sarah
    Pirotta, Nicoletta
    Squires, Matthew
    Shi, Michael
    Angevin, Eric
    CLINICAL CANCER RESEARCH, 2014, 20 (11) : 3012 - 3022
  • [32] CTEN and LKB1: novel tumor biomarkers for breast cancer implications of resistance and response to tyrosine kinase inhibitor (TKI)-based therapies in breast cancer
    Yarden, Y.
    Shell, S. A.
    Spector, N. L.
    Bacus, S. S.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S159 - S159
  • [33] Tyrosine kinase inhibitor (TKI)-induced macrocytosis
    Schallier, D.
    Trullemans, F.
    Fontaine, C.
    Decoster, L.
    De Greve, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 136 - 136
  • [34] Tyrosine kinase inhibitor (tki)-induced macrocytosis
    Schallier, D.
    Trullemans, F.
    Fontaine, C.
    Decoster, L.
    De Greve, J.
    ACTA CLINICA BELGICA, 2010, 65 (02): : 156 - 156
  • [35] Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer
    Lee, Choong-Kun
    Lee, Myung Eun
    Lee, Won Suk
    Kim, Jeong Min
    Park, Kyu Hyun
    Kim, Tae Soo
    Lee, Kang Young
    Ahn, Joong Bae
    Chung, Hyun Cheol
    Rha, Sun Young
    AMERICAN JOURNAL OF CANCER RESEARCH, 2015, 5 (01): : 72 - 86
  • [36] Response to a Novel Multitargeted Tyrosine Kinase Inhibitor Pazopanib in Metastatic Merkel Cell Carcinoma
    Davids, Matthew
    Charlton, Amanda
    Ng, Swee-Siang
    Chong, Mei-Ling
    Laubscher, Kevin
    Dar, Mohammed
    Hodge, Jeffrey
    Soong, Richie
    Goh, Boon Cher
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) : E97 - E100
  • [37] Dovitinib (TKI258), a dual inhibitor of FGFR and VEGFR, induces tumor growth suppression in xenograft models of human bladder cancer
    Shi, Michael M.
    Linnartz, Ronald
    Versace, Richard
    Brueggen, Joseph
    Chatenay-Rivauday, Christian
    Stamm, Christelle
    Dugan, Margaret
    Porta, Diana Graus
    CANCER RESEARCH, 2011, 71
  • [38] Tyrosine kinase inhibitor TKI-258 inhibits cell motility in oral squamous cell carcinoma in vitro
    Dias Maciel Carneiro, Anna Cecilia
    da Silveira, Isadora Caixeta
    Rezende, Arthur Silva
    Oliveira Silva, Bruna Raphaela
    Crema, Virginia Oliveira
    JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2017, 46 (07) : 484 - 488
  • [39] Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer
    Roviello, Giandomenico
    Ravelli, Andrea
    Polom, Karol
    Petrioli, Roberto
    Marano, Luigi
    Marrelli, Daniele
    Roviello, Franco
    Generali, Daniele
    CANCER LETTERS, 2016, 372 (02) : 187 - 191
  • [40] Phase II study of the multikinase inhibitor dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine resistant HER2-/HR+ breast cancer
    Andre, Fabrice
    Greil, Richard
    Denduluri, Neelima
    Yovine, Alejandro Javier
    Reddick, Cathy
    Squires, Matthew
    Zhang, Yong
    Blackwell, Kimberly
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345